About
Novel topical dermatological therapies
Areas of Focus
Categories
Small Molecule PharmaceuticalMidwest
Team (21)
Ajay Aggarwal
Senior Vice President, Clinical Development
Aclaris Therapeutics
executive
Anand Mehra, M.D.
Director
Aclaris Therapeutics
team_member
Andrew Schiff, M.D.
Director
Aclaris Therapeutics
team_member
Christopher Molineaux
Lead Independent Director
Aclaris Therapeutics
lead_independent_directorboard_member
Dr. Neal Walker
Chief Executive Officer and Chair of Board of Directors
Aclaris Therapeutics
board_chairexecutive
Hugh Davis, Ph.D.
Director, President & Chief Operating Officer
Aclaris Therapeutics
executive
Clinical Trials (36)
View allTotal Trials
36
As Lead Sponsor
33
As Collaborator
3
Total Enrollment
5,037
By Phase
PHASE2: 24PHASE1: 2PHASE1/PHASE2: 2PHASE3: 6PHASE4: 2
By Status
COMPLETED: 28TERMINATED: 4RECRUITING: 3WITHDRAWN: 1
Clinical Trials Pipeline36 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
Today
Hover over trial bars to see details
Recent Trials
NCT07011706Lead Sponsor
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
PHASE2Recruiting
96 participants
Started: May 30, 2025 · Completed: Oct 31, 2026
NCT06648434Collaborator
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
PHASE1Recruiting
51 participants
Started: May 15, 2025 · Completed: May 31, 2030
NCT06374459Collaborator
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
PHASE1/PHASE2Recruiting
152 participants
Started: Jan 30, 2025 · Completed: May 31, 2032
NCT06585202Lead Sponsor
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
PHASE2Completed
14 participants
Started: Aug 19, 2024 · Completed: Mar 27, 2025
NCT05791474Collaborator
ATI-2231 in Advanced Solid Tumor Malignancies
PHASE1Withdrawn
Started: Nov 15, 2023 · Completed: Jun 30, 2025
Locations (1)
Headquarters
St. Louis, MO, United States
Map
Loading map...